Skip to content

The Value of S100A9, ORM2, SOD1 and IL1F6 in Evaluating the Prognosis of Secondary Pulmonary Tuberculosis

The Value of S100A9, ORM2, SOD1 and IL1F6 in Evaluating the Prognosis of Secondary Pulmonary Tuberculosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020378
Enrollment
Unknown
Registered
2018-12-27
Start date
2018-12-27
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Gold Standard:Clinical outcome
protein&#32
S100A9,&#32
ORM2,&#32
IL1F6&#32
and&#32
SOD1&#32

Sponsors

Beijing Chest Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: The patients were diagnosed with TB according to combined clinical criteria from the World Health Organization. Included patients with pulmonary TB had a positive sputum smear or culture result. Patients with pulmonary TB were further stratified according to disease severity, into a severe pulmonary TB (STB) group and a mild pulmonary TB (MTB) group. Patients were considered to be STB if three or more lung lobe alterations were observed in a chest computed tomography (CT) scan, with respiratory failure or hypoxemia

Exclusion criteria

Exclusion criteria: (1) Aged < 18 years old; (2) Patients with malignant tumors; (3) Immune system diseases or those receiving immunotherapy; (4) HIV, hepatitis B and hepatitis C virus infection; (5) Complications during pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
SPE, SEN, ACC, AUC of ROC;plasma protein S100A9, ORM2, IL1F6 and SOD1 levels;

Countries

China

Contacts

Public ContactLIUQIUYUE

Beijing Chest Hospital, Capital Medical University

28195059@qq.com+86 010 89509052

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026